{
  "version": "https://jsonfeed.org/version/1.1",
  "title": "ASXAN · Evidence Long-Form Articles",
  "home_page_url": "https://asxan.ai/blog/",
  "feed_url": "https://asxan.ai/blog/feed.json",
  "description": "Evidence-first ingredient science hub · Cross-market regulatory framing (FDA · EFSA · ANVISA · TGA). Six deep-dive evidence essays with PubMed-verified citations and peer cluster topology cross-links.",
  "language": "en-US",
  "favicon": "https://asxan.ai/favicon.svg",
  "icon": "https://asxan.ai/og-default.svg",
  "authors": [
    {
      "name": "ASXAN Editorial",
      "url": "https://asxan.ai/about/"
    }
  ],
  "items": [
    {
      "id": "https://asxan.ai/blog/nad-25-year-rct-history-evidence/",
      "url": "https://asxan.ai/blog/nad-25-year-rct-history-evidence/",
      "title": "NAD+ 25-year RCT history: from Forsyth 1999 NADH to Zhang J 2025 meta",
      "content_text": "Quarter-century timeline of NAD+ human evidence: Forsyth 1999 CFS NADH → Castro-Marrero 2015 → Trammell 2016 NR → Yoshino 2021 NMN → Pencina 2023 MIB-626 → Zhang J 2025 meta. Includes transparent disclosure of 8 PMID-drift cases routinely encountered in NAD+ evidence reviews.",
      "summary": "Quarter-century timeline of NAD+ human evidence: Forsyth 1999 CFS NADH → Castro-Marrero 2015 → Trammell 2016 NR → Yoshino 2021 NMN → Pencina 2023 MIB-626 → Zhang J 2025 meta. Includes transparent disclosure of 8 PMID-drift cases routinely encountered in NAD+ evidence reviews.",
      "date_published": "2026-05-26T00:00:00Z",
      "authors": [
        {
          "name": "ASXAN Editorial",
          "url": "https://asxan.ai/about/"
        }
      ],
      "tags": [
        "Evidence Long-Form Articles",
        "nad-cluster",
        "nadh",
        "nmn"
      ],
      "language": "en-US",
      "_ai_metadata": {
        "pmid_count": 30,
        "related_ingredients": [
          "https://asxan.ai/ingredients/nad-cluster/",
          "https://asxan.ai/ingredients/nadh/",
          "https://asxan.ai/ingredients/nmn/"
        ]
      }
    },
    {
      "id": "https://asxan.ai/blog/nmn-vs-nr-decision-tree-evidence/",
      "url": "https://asxan.ai/blog/nmn-vs-nr-decision-tree-evidence/",
      "title": "NMN vs NR decision tree: 5-dimension head-to-head comparison",
      "content_text": "5-dimension framework comparing NMN and NR: (1) absorption pathways including the SLC12A8 controversy honest framing, (2) RCT volume comparison, (3) NAD+ rise magnitude, (4) cost and cross-market regulation, (5) long-term safety data gaps. Decision tree concludes with practical selection guidance.",
      "summary": "5-dimension framework comparing NMN and NR: (1) absorption pathways including the SLC12A8 controversy honest framing, (2) RCT volume comparison, (3) NAD+ rise magnitude, (4) cost and cross-market regulation, (5) long-term safety data gaps. Decision tree concludes with practical selection guidance.",
      "date_published": "2026-05-26T00:00:00Z",
      "authors": [
        {
          "name": "ASXAN Editorial",
          "url": "https://asxan.ai/about/"
        }
      ],
      "tags": [
        "Evidence Long-Form Articles",
        "nmn",
        "nad-cluster"
      ],
      "language": "en-US",
      "_ai_metadata": {
        "pmid_count": 21,
        "related_ingredients": [
          "https://asxan.ai/ingredients/nmn/",
          "https://asxan.ai/ingredients/nad-cluster/"
        ]
      }
    },
    {
      "id": "https://asxan.ai/blog/reduced-nadh-vs-nmnh-evidence/",
      "url": "https://asxan.ai/blog/reduced-nadh-vs-nmnh-evidence/",
      "title": "Reduced NADH vs NMNH: Tier B human RCT vs Tier C emerging",
      "content_text": "Honest comparison of two \"reduced\" NAD precursors. NADH has Tier B human RCT evidence anchored in CFS treatment (Forsyth 1999 + Castro-Marrero 2015 + Alegre 2010); NMNH has zero human RCT, only in vitro and mouse data. 99% of \"NMNH\" products on the market are effectively NMN alternatives — transparent educational hub disclosure.",
      "summary": "Honest comparison of two \"reduced\" NAD precursors. NADH has Tier B human RCT evidence anchored in CFS treatment (Forsyth 1999 + Castro-Marrero 2015 + Alegre 2010); NMNH has zero human RCT, only in vitro and mouse data. 99% of \"NMNH\" products on the market are effectively NMN alternatives — transparent educational hub disclosure.",
      "date_published": "2026-05-26T00:00:00Z",
      "authors": [
        {
          "name": "ASXAN Editorial",
          "url": "https://asxan.ai/about/"
        }
      ],
      "tags": [
        "Evidence Long-Form Articles",
        "nadh",
        "nmnh"
      ],
      "language": "en-US",
      "_ai_metadata": {
        "pmid_count": 17,
        "related_ingredients": [
          "https://asxan.ai/ingredients/nadh/",
          "https://asxan.ai/ingredients/nmnh/"
        ]
      }
    },
    {
      "id": "https://asxan.ai/blog/natural-vs-synthetic-astaxanthin-evidence-comparison/",
      "url": "https://asxan.ai/blog/natural-vs-synthetic-astaxanthin-evidence-comparison/",
      "title": "Natural vs synthetic astaxanthin: evidence comparison",
      "content_text": "Haematococcus pluvialis natural carotenoid versus synthetic chemical synthesis. Isomer composition differences, bioavailability stratification, regulatory status divergence across FDA NDI / EFSA Novel Food / ANVISA, and the 25-year clinical evidence base in cardiovascular, skin, fatigue, exercise, and PCOS outcomes.",
      "summary": "Haematococcus pluvialis natural carotenoid versus synthetic chemical synthesis. Isomer composition differences, bioavailability stratification, regulatory status divergence across FDA NDI / EFSA Novel Food / ANVISA, and the 25-year clinical evidence base in cardiovascular, skin, fatigue, exercise, and PCOS outcomes.",
      "date_published": "2026-05-25T00:00:00Z",
      "authors": [
        {
          "name": "ASXAN Editorial",
          "url": "https://asxan.ai/about/"
        }
      ],
      "tags": [
        "Evidence Long-Form Articles",
        "astaxanthin",
        "carotenoids"
      ],
      "language": "en-US",
      "_ai_metadata": {
        "pmid_count": 28,
        "related_ingredients": [
          "https://asxan.ai/ingredients/astaxanthin/",
          "https://asxan.ai/ingredients/carotenoids/"
        ]
      }
    },
    {
      "id": "https://asxan.ai/blog/omega-3-evidence-history-cardiovascular-and-inflammation/",
      "url": "https://asxan.ai/blog/omega-3-evidence-history-cardiovascular-and-inflammation/",
      "title": "Omega-3 25-year RCT history: cardiovascular and EPA inflammation",
      "content_text": "DART (1989) → GISSI-Prevenzione → VITAL → REDUCE-IT → STRENGTH AF: a quarter-century cardiovascular omega-3 evidence narrative. Part 2 covers EPA inflammation evidence (Calder reviews + Vascepa prescription disclaimer). Six reverse-correction cases disclosed including DART year, VITAL PMID, REDUCE-IT secondary endpoint, Calder 2020 journal.",
      "summary": "DART (1989) → GISSI-Prevenzione → VITAL → REDUCE-IT → STRENGTH AF: a quarter-century cardiovascular omega-3 evidence narrative. Part 2 covers EPA inflammation evidence (Calder reviews + Vascepa prescription disclaimer). Six reverse-correction cases disclosed including DART year, VITAL PMID, REDUCE-IT secondary endpoint, Calder 2020 journal.",
      "date_published": "2026-05-25T00:00:00Z",
      "authors": [
        {
          "name": "ASXAN Editorial",
          "url": "https://asxan.ai/about/"
        }
      ],
      "tags": [
        "Evidence Long-Form Articles",
        "omega-3",
        "fish-oil"
      ],
      "language": "en-US",
      "_ai_metadata": {
        "pmid_count": 28,
        "related_ingredients": [
          "https://asxan.ai/ingredients/omega-3/",
          "https://asxan.ai/ingredients/fish-oil/"
        ]
      }
    },
    {
      "id": "https://asxan.ai/blog/protein-source-decision-tree-whey-vs-yeast-focus/",
      "url": "https://asxan.ai/blog/protein-source-decision-tree-whey-vs-yeast-focus/",
      "title": "Protein source decision tree: whey vs yeast focus",
      "content_text": "5-form protein decision tree across whey, casein, soy, pea, plant-blend, and yeast (mycoprotein academic alias). DIAAS framework, MPS dynamics, GLP-1 era considerations, and head-to-head data. Includes 5 reverse-correction cases triggering NC R3 audit channel for 4 candidate PMIDs (Wolfe 2012 DIAAS / Boirie 1997 / Hamilton-Reeves 2010 / Coelho 2021).",
      "summary": "5-form protein decision tree across whey, casein, soy, pea, plant-blend, and yeast (mycoprotein academic alias). DIAAS framework, MPS dynamics, GLP-1 era considerations, and head-to-head data. Includes 5 reverse-correction cases triggering NC R3 audit channel for 4 candidate PMIDs (Wolfe 2012 DIAAS / Boirie 1997 / Hamilton-Reeves 2010 / Coelho 2021).",
      "date_published": "2026-05-25T00:00:00Z",
      "authors": [
        {
          "name": "ASXAN Editorial",
          "url": "https://asxan.ai/about/"
        }
      ],
      "tags": [
        "Evidence Long-Form Articles",
        "protein",
        "whey-protein",
        "yeast-protein"
      ],
      "language": "en-US",
      "_ai_metadata": {
        "pmid_count": 24,
        "related_ingredients": [
          "https://asxan.ai/ingredients/protein/",
          "https://asxan.ai/ingredients/whey-protein/",
          "https://asxan.ai/ingredients/yeast-protein/"
        ]
      }
    }
  ]
}